Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.

Abstract

Mutations in fms-like tyrosine kinase 3 (FLT3) gene are common genomic alterations in acute myeloid leukemia (AML). FLT3 internal tandem duplication mutations (FLT3-ITD) have consistently been shown to be adversely prognostic, particularly those with high allelic ratio (AR). Current AML treatment strategies, including high dose cytarabine, purine analogs, FLT3 inhibitors (FLT3i), and with or without allogeneic stem cell transplant (SCT) have been shown to improve the outcomes in patients with FLT3 mutations. We analyzed a consecutive cohort of newly diagnosed patients with AML treated at a large academic medical center from January 2012 to January 2020. A total of 1576 patients with a new diagnosis of AML were reviewed. Among these, 1438 (91%) had molecular testing for FLT3 mutations and 21% (304/1438) had an FLT3 mutation, including 17% with an FLT3-ITD mutation. We show that FLT3-ITD high AR with NPM1 wild-type have significantly improved survival compared with other European LeukemiaNet (ELN) adverse risk disease. In multivariable cox proportional hazards model of patients receiving intensive or low-intensity induction regimens, FLT3 mutations did not have prognostic significance. The use of allogeneic SCT in CR1 for patients with FLT3 mutations appears to improve survival, particularly in those with ELN adverse risk disease. Overall, this data highlights the changing prognostic impact of FLT3 mutations in a contemporary era with appropriate use of induction therapy combined with targeted agents and allogenic SCT.

• Authors: Patrick K Reville, Koji Sasaki, Hagop M Kantarjian, Naval G Daver, Musa Yilmaz, Courtney D Dinardo, Nicholas J Short, Gautam Borthakur, Naveen Pemmaraju, Rohtesh S Mehta, Sherry Pierce, Sergej N Konoplev, Joseph D Khoury, Guillermo Garcia-Manero, Marina Y Konopleva, Elias Jabbour, Farhad Ravandi, Tapan M Kadia
• Journal: American journal of hematology (Am J Hematol) Vol. 97 Issue 3 Pg. 329-337 (03 01 2022) ISSN: 1096-8652 [Electronic] United States
• PMID: 34981570 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: © 2022 Wiley Periodicals LLC.

Chemical References

• FLT3 protein, human
• fms-Like Tyrosine Kinase 3

Topics

• Allografts
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Disease-Free Survival
• Female
• Humans
• Infant
• Leukemia, Myeloid, Acute (enzymology, genetics, mortality, therapy)
• Male
• Mutation
• Risk Assessment
• Stem Cell Transplantation
• Survival Rate
• fms-Like Tyrosine Kinase 3 (genetics)